Special Report: KRAS Finding Changes Oncology Practice But Poses Profound Regulatory Dilemma
FDA Concerned About Data-Dredging In Drug-Diagnostic Applications
Government Offers Two Approval Standards For Assays: CLIA, FDA
FDA Ponders Standards For “Retrospective Prospective” Studies
ODAC Discussion: NCI’s Richard Simon Cautions About Rules Of Thumb
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Pour a Scotch, we’re talking clinical trials and prediction markets
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Johnson and Johnson reaches $5.5B settlement deal over talc lawsuits
- Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives









